Amphastar Pharmaceuticals (NASDAQ:AMPH) Trading 3% Higher

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report)'s stock price traded up 3% during mid-day trading on Monday . The company traded as high as $40.87 and last traded at $40.81. 174,550 shares traded hands during mid-day trading, a decline of 62% from the average session volume of 464,657 shares. The stock had previously closed at $39.62.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. assumed coverage on Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They issued an "overweight" rating and a $60.00 price target on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, April 10th. Finally, StockNews.com lowered Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, February 29th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $66.00.

Amphastar Pharmaceuticals Stock Performance

The stock has a market cap of $1.96 billion, a PE ratio of 15.81, a P/E/G ratio of 0.94 and a beta of 0.85. The company has a quick ratio of 1.70, a current ratio of 2.17 and a debt-to-equity ratio of 0.92. The stock has a 50-day moving average of $47.08 and a 200 day moving average of $51.34.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last announced its quarterly earnings data on Wednesday, February 28th. The company reported $0.81 EPS for the quarter, missing analysts' consensus estimates of $0.84 by ($0.03). Amphastar Pharmaceuticals had a return on equity of 26.95% and a net margin of 21.34%. The company had revenue of $178.11 million for the quarter, compared to analysts' expectations of $174.90 million. Equities analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.42 EPS for the current fiscal year.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 12,500 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total value of $589,750.00. Following the sale, the director now owns 21,326 shares in the company, valued at $1,006,160.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 12,500 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total value of $589,750.00. Following the sale, the director now owns 21,326 shares in the company, valued at $1,006,160.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Floyd F. Petersen sold 500 shares of Amphastar Pharmaceuticals stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $53.10, for a total value of $26,550.00. Following the completion of the sale, the director now owns 80,333 shares in the company, valued at approximately $4,265,682.30. The disclosure for this sale can be found here. Insiders have sold 14,000 shares of company stock worth $660,860 over the last quarter. 27.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AMPH. Shaker Investments LLC OH boosted its position in shares of Amphastar Pharmaceuticals by 136.0% during the 4th quarter. Shaker Investments LLC OH now owns 49,078 shares of the company's stock worth $3,035,000 after acquiring an additional 28,283 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its position in shares of Amphastar Pharmaceuticals by 44.8% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 554,850 shares of the company's stock worth $25,518,000 after acquiring an additional 171,642 shares in the last quarter. Walleye Capital LLC acquired a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter worth about $1,833,000. Charles Schwab Investment Management Inc. boosted its position in shares of Amphastar Pharmaceuticals by 7.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 352,378 shares of the company's stock worth $16,206,000 after acquiring an additional 24,116 shares in the last quarter. Finally, Rafferty Asset Management LLC acquired a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter worth about $205,000. 65.09% of the stock is owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.